GlassScriptPhysician profile
Jeffrey H Johnson
NPI 1285635961
$94,290.23
in general payments reported to CMS, 2019-2025
35 companies · $13K in 2025
The $13K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,433 · 2020: $2,598 · 2021: $13K · 2022: $17K · 2023: $19K · 2024: $20K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $42K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,500 · Food and Beverage: $3,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $42,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,500.00 |
| Food and Beverage | $3,060.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daxor Corporation | $52,146.78 | 2022-2025 | Bva-100 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21,560.62 | 2019-2025 | Lifevest |
| Esperion Therapeutics, INC. | $9,580.72 | 2021 | |
| Novartis Pharmaceuticals Corporation | $7,465.67 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $556.51 | 2019-2023 | Xarelto |
| Amgen INC. | $505.49 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $345.98 | 2019-2024 | |
| Abbott Laboratories | $269.38 | 2019-2023 | Optis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.17 | 2019-2023 | Jardiance |
| Boston Scientific Corporation | $236.16 | 2019-2025 | Farapulse, Watchman Flx, Bodyguardian |
| Astrazeneca Pharmaceuticals LP | $162.79 | 2019-2024 | Wainua |
| Atricure, INC. | $148.49 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $129.17 | 2019-2025 | Uptravi, Opsumit |
| Sanofi-Aventis U.S. LLC | $119.81 | 2019-2024 | |
| Inspire Medical Systems, INC. | $115.36 | 2024-2025 | Inspire |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $111.87 | 2019-2024 | Eliquis, Camzyos |
| Heartflow, INC. | $67.75 | 2025 | |
| Abiomed | $55.91 | 2023 | Impella |
| Amarin Pharma, INC. | $52.32 | 2019-2022 | |
| Gilead Sciences, INC. | $52.18 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $42.52 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $41.57 | 2023 | Arcalyst |
| Akcea Therapeutics, INC. | $40.91 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $28.05 | 2019 | |
| Irhythm Technologies, INC. | $25.06 | 2020 | |
| Teleflex LLC | $24.15 | 2019 | |
| Daiichi Sankyo INC. | $23.68 | 2023 | Injectafer |
| Lundbeck LLC | $23.28 | 2019 | |
| Vital Connect, INC | $20.00 | 2024 | Vitalpatch Rtm |
| Alnylam Pharmaceuticals INC. | $19.20 | 2025 | Amvuttra |
| Scpharmaceuticals INC. | $19.00 | 2025 | |
| Dynavax Technologies Corporation | $17.07 | 2025 | Heplisav-B |
| Genzyme Corporation | $15.71 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.78 | 2023 | |
| Philips North America LLC | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.